• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

CAB39 Polyklonaler Antikörper

CAB39 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Ratte

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 31710-1-PBS

Synonyme

Filter:
  • Western Blot (WB) analysis of various lysates using CAB39 Polyclonal antibody (31710-1-AP)

    WB analysis using 31710-1-AP (same clone as 31710-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 31710-1-AP (CAB39 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 31710-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

31710-1-PBS bindet in WB, Indirect ELISA CAB39 und zeigt Reaktivität mit human, Ratten

Getestete Reaktivität human, Ratte
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen CAB39 fusion protein Ag36153
Vollständiger Name calcium binding protein 39
Beobachtetes Molekulargewicht 39-40 kDa
GenBank-ZugangsnummerBC020570
Gene symbol CAB39
Gene ID (NCBI) 51719
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CAB39 (Calcium-binding protein 39), also called MO25, is a component of the complex that binds and activates STK11/LKB1. It is required to stabilize the interaction between CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta) and STK11/LKB1 (PMID: 19892943).